Showing results (401-410 of 494) with videos related to

Sort By:
Pageof 50
Annals of Surgical Oncology|February 1, 2025
Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 TrialCharles H Yoon, Merrick I Ross, Brian R Gastman, et al.
JAMA Oncology|October 16, 2025
Guidelines for Next-Generation Sequencing in Sarcoma Diagnosis and Treatment: A Consensus ReviewCésar Serrano, Sebastian Bauer, Jean-Yves Blay, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Cancer|November 18, 2020
Defining the role of neoadjuvant systemic therapy in high-risk retroperitoneal sarcoma: A multi-institutional study from the Transatlantic Australasian Retroperitoneal Sarcoma Working GroupWilliam W Tseng, Francesco Barretta, Lorenzo Conti, et al.
The New England Journal of Medicine|June 6, 2012
Improved survival with MEK inhibition in BRAF-mutated melanomaKeith T Flaherty, Caroline Robert, Peter Hersey, et al.
Eclinicalmedicine|June 16, 2025
Defining benchmark values for outcomes of comprehensive resection of primary retroperitoneal liposarcoma: a retrospective multicenter studyFabio Tirotta, Marco Fiore, Sylvie Bonvalot, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2024
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor: A Phase I Study of VimseltinibHans Gelderblom, Albiruni A Razak, Matthew H Taylor, et al.
Critical Reviews in Oncology/Hematology|February 21, 2018
ECCO essential requirements for quality cancer care: MelanomaMichel W Wouters, Olivier Michielin, Esther Bastiaannet, et al.
Cancer|March 5, 2020
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupLorenzo D'Ambrosio, Nathan Touati, Jean-Yves Blay, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2019
Predicting Survival in Patients Undergoing Resection for Locally Recurrent Retroperitoneal Sarcoma: A Study and Novel Nomogram from TARPSWGChandrajit P Raut, Dario Callegaro, Rosalba Miceli, et al.
Pageof 50